Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2022.2793
Abstract: This post hoc analysis of the randomized clinical trial, Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ), investigates if amyloid reduction from donanemab treatment is associated with slowing of tau pathology and… read more here.
Keywords: reduction donanemab; donanemab treatment; amyloid reduction; pathology ... See more keywords
Molecular pathology and clinical implications of diffuse glioma
Sign Up to like & getrecommendations! Published in 2022 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000002446
Abstract: Abstract The prognosis for diffusely infiltrating gliomas at World Health Organization (WHO) grade 2–4 remains dismal due to their heterogeneity. The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification.… read more here.
Keywords: clinical implications; diffuse glioma; implications diffuse; molecular pathology ... See more keywords
MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
Sign Up to like & getrecommendations! Published in 2020 at "Acta Neuropathologica Communications"
DOI: 10.1186/s40478-020-01097-z
Abstract: The microtubule-associated protein tau ( MAPT ) H1 haplotype is the strongest genetic risk factor for corticobasal degeneration (CBD). However, the specific H1 subhaplotype association is not well defined, and it is not clear whether… read more here.
Keywords: risk; cbd; tau pathology; pathology clinical ... See more keywords